Medtronic plc

Medtronic plc develops, manufactures, and sells device-based medical therapies across four primary operating segments. The Cardiovascular Portfolio includes implantable cardiac devices such as pacemakers, defibrillators, and cardiac resynchronization therapy systems, alongside ablation products, insertable cardiac monitors, aortic valves, endovascular stent grafts, and percutaneous coronary intervention products. The Neuroscience Portfolio encompasses spinal cord stimulation systems, brain modulation devices, implantable drug infusion systems, nerve ablation systems, and interventional products for use by neurosurgeons, neurologists, pain specialists, and other surgical practitioners. The Medical Surgical Portfolio provides surgical stapling devices, vessel sealing instruments, robotic-assisted surgery products, mesh implants, electrosurgery equipment, and patient monitoring devices. The Diabetes Operating Unit manufactures insulin pumps, continuous glucose monitoring systems, and smart insulin pens.

The company operates across the United States, Ireland, and international markets, serving healthcare systems, physicians, clinicians, and patients. With approximately 95,000 full-time employees, Medtronic maintains a substantial global presence in the medical devices sector. Products are distributed to surgeons, specialists, and healthcare facilities across multiple therapeutic areas, including cardiology, neurosurgery, orthopedic surgery, general surgery, and diabetes care management. The company was founded in 1949 and maintains its headquarters in Galway, Ireland.